カテゴリー： QYResearch, 世界, 医療/バイオ

潰瘍性大腸炎治療オプションのグローバル市場2023年：抗炎症薬、免疫抑制剤、その他医薬品

◆英語タイトル：Global Ulcerative Colitis Treatment Options Market Research Report 2023
	◆商品コード：QYR23MA8916 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2023年3月 ◆ページ数：100 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD2,900 ⇒換算￥440,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD4,350 ⇒換算￥661,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD5,800 ⇒換算￥881,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の潰瘍性大腸炎治療オプション市場について調査・分析し、世界の潰瘍性大腸炎治療オプション市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（抗炎症薬、免疫抑制剤、その他医薬品）、用途別セグメント分析（病院、クリニック、ドラッグストア、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Novartis、Roche、Sanofi、GSK、AstraZeneca、MSD、Johnson & Johnson、Bayer、AbbVie、Eli Lilly and Company、Amgen、Takeda Pharmaceuticals Company、Ferring Pharmaceuticals、InDeX Pharmaceuticalsなどが含まれています。世界の潰瘍性大腸炎治療オプション市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、潰瘍性大腸炎治療オプション市場規模を推定する際に考慮しました。

・潰瘍性大腸炎治療オプション市場の概要
- 潰瘍性大腸炎治療オプションのタイプ別セグメント
- 世界の潰瘍性大腸炎治療オプション市場規模：タイプ別分析（抗炎症薬、免疫抑制剤、その他医薬品）
- 潰瘍性大腸炎治療オプションの用途別セグメント
- 世界の潰瘍性大腸炎治療オプション市場規模：用途別分析（病院、クリニック、ドラッグストア、その他）
- 世界の潰瘍性大腸炎治療オプション市場規模予測（2018年-2029年）

・潰瘍性大腸炎治療オプション市場の成長トレンド
- 潰瘍性大腸炎治療オプションの地域別市場規模（2018年-2029年）
- 潰瘍性大腸炎治療オプション市場ダイナミクス
- 潰瘍性大腸炎治療オプションの業界動向
- 潰瘍性大腸炎治療オプション市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・タイプ別セグメント：抗炎症薬、免疫抑制剤、その他医薬品
- 世界の潰瘍性大腸炎治療オプションのタイプ別市場規模（2018年-2023年）
- 世界の潰瘍性大腸炎治療オプションのタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、クリニック、ドラッグストア、その他
- 世界の潰瘍性大腸炎治療オプションの用途別市場規模（2018年-2023年）
- 世界の潰瘍性大腸炎治療オプションの用途別市場規模（2024年-2029年）

・潰瘍性大腸炎治療オプションの地域別市場規模
- 北米の潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- アメリカの潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- ヨーロッパの潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- アジア太平洋の潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- 中国の潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- 日本の潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- 韓国の潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- インドの潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- オーストラリアの潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- 中南米の潰瘍性大腸炎治療オプション市場規模（2018年-2029年）
- 中東・アフリカの潰瘍性大腸炎治療オプション市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Pfizer、Novartis、Roche、Sanofi、GSK、AstraZeneca、MSD、Johnson & Johnson、Bayer、AbbVie、Eli Lilly and Company、Amgen、Takeda Pharmaceuticals Company、Ferring Pharmaceuticals、InDeX Pharmaceuticals

・アナリストの観点/結論

・調査方法とデータソース

Highlights
The global Ulcerative Colitis Treatment Options market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Ulcerative Colitis Treatment Options is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Ulcerative Colitis Treatment Options is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Ulcerative Colitis Treatment Options in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Ulcerative Colitis Treatment Options include Pfizer, Novartis, Roche, Sanofi, GSK, AstraZeneca, MSD, Johnson & Johnson and Bayer, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ulcerative Colitis Treatment Options, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ulcerative Colitis Treatment Options.
The Ulcerative Colitis Treatment Options market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Ulcerative Colitis Treatment Options market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ulcerative Colitis Treatment Options companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Novartis
Roche
Sanofi
GSK
AstraZeneca
MSD
Johnson & Johnson
Bayer
AbbVie
Eli Lilly and Company
Amgen
Takeda Pharmaceuticals Company
Ferring Pharmaceuticals
InDeX Pharmaceuticals
Segment by Type
Anti-inflammatory Drugs
Immune System Suppressors
Other Medications
Segment by Application
Hospital
Clinic
Drugs Store
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ulcerative Colitis Treatment Options companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ulcerative Colitis Treatment Options Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Anti-inflammatory Drugs
1.2.3 Immune System Suppressors
1.2.4 Other Medications
1.3 Market by Application
1.3.1 Global Ulcerative Colitis Treatment Options Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drugs Store
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ulcerative Colitis Treatment Options Market Perspective (2018-2029)
2.2 Ulcerative Colitis Treatment Options Growth Trends by Region
2.2.1 Global Ulcerative Colitis Treatment Options Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Ulcerative Colitis Treatment Options Historic Market Size by Region (2018-2023)
2.2.3 Ulcerative Colitis Treatment Options Forecasted Market Size by Region (2024-2029)
2.3 Ulcerative Colitis Treatment Options Market Dynamics
2.3.1 Ulcerative Colitis Treatment Options Industry Trends
2.3.2 Ulcerative Colitis Treatment Options Market Drivers
2.3.3 Ulcerative Colitis Treatment Options Market Challenges
2.3.4 Ulcerative Colitis Treatment Options Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ulcerative Colitis Treatment Options Players by Revenue
3.1.1 Global Top Ulcerative Colitis Treatment Options Players by Revenue (2018-2023)
3.1.2 Global Ulcerative Colitis Treatment Options Revenue Market Share by Players (2018-2023)
3.2 Global Ulcerative Colitis Treatment Options Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ulcerative Colitis Treatment Options Revenue
3.4 Global Ulcerative Colitis Treatment Options Market Concentration Ratio
3.4.1 Global Ulcerative Colitis Treatment Options Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ulcerative Colitis Treatment Options Revenue in 2022
3.5 Ulcerative Colitis Treatment Options Key Players Head office and Area Served
3.6 Key Players Ulcerative Colitis Treatment Options Product Solution and Service
3.7 Date of Enter into Ulcerative Colitis Treatment Options Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ulcerative Colitis Treatment Options Breakdown Data by Type
4.1 Global Ulcerative Colitis Treatment Options Historic Market Size by Type (2018-2023)
4.2 Global Ulcerative Colitis Treatment Options Forecasted Market Size by Type (2024-2029)
5 Ulcerative Colitis Treatment Options Breakdown Data by Application
5.1 Global Ulcerative Colitis Treatment Options Historic Market Size by Application (2018-2023)
5.2 Global Ulcerative Colitis Treatment Options Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Ulcerative Colitis Treatment Options Market Size (2018-2029)
6.2 North America Ulcerative Colitis Treatment Options Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Ulcerative Colitis Treatment Options Market Size by Country (2018-2023)
6.4 North America Ulcerative Colitis Treatment Options Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ulcerative Colitis Treatment Options Market Size (2018-2029)
7.2 Europe Ulcerative Colitis Treatment Options Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Ulcerative Colitis Treatment Options Market Size by Country (2018-2023)
7.4 Europe Ulcerative Colitis Treatment Options Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ulcerative Colitis Treatment Options Market Size (2018-2029)
8.2 Asia-Pacific Ulcerative Colitis Treatment Options Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Ulcerative Colitis Treatment Options Market Size by Region (2018-2023)
8.4 Asia-Pacific Ulcerative Colitis Treatment Options Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ulcerative Colitis Treatment Options Market Size (2018-2029)
9.2 Latin America Ulcerative Colitis Treatment Options Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Ulcerative Colitis Treatment Options Market Size by Country (2018-2023)
9.4 Latin America Ulcerative Colitis Treatment Options Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ulcerative Colitis Treatment Options Market Size (2018-2029)
10.2 Middle East & Africa Ulcerative Colitis Treatment Options Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Ulcerative Colitis Treatment Options Market Size by Country (2018-2023)
10.4 Middle East & Africa Ulcerative Colitis Treatment Options Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Ulcerative Colitis Treatment Options Introduction
11.1.4 Pfizer Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Ulcerative Colitis Treatment Options Introduction
11.2.4 Novartis Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Roche
11.3.1 Roche Company Detail
11.3.2 Roche Business Overview
11.3.3 Roche Ulcerative Colitis Treatment Options Introduction
11.3.4 Roche Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.3.5 Roche Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Ulcerative Colitis Treatment Options Introduction
11.4.4 Sanofi Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.4.5 Sanofi Recent Development
11.5 GSK
11.5.1 GSK Company Detail
11.5.2 GSK Business Overview
11.5.3 GSK Ulcerative Colitis Treatment Options Introduction
11.5.4 GSK Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.5.5 GSK Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Ulcerative Colitis Treatment Options Introduction
11.6.4 AstraZeneca Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.6.5 AstraZeneca Recent Development
11.7 MSD
11.7.1 MSD Company Detail
11.7.2 MSD Business Overview
11.7.3 MSD Ulcerative Colitis Treatment Options Introduction
11.7.4 MSD Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.7.5 MSD Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Ulcerative Colitis Treatment Options Introduction
11.8.4 Johnson & Johnson Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.8.5 Johnson & Johnson Recent Development
11.9 Bayer
11.9.1 Bayer Company Detail
11.9.2 Bayer Business Overview
11.9.3 Bayer Ulcerative Colitis Treatment Options Introduction
11.9.4 Bayer Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.9.5 Bayer Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Detail
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Ulcerative Colitis Treatment Options Introduction
11.10.4 AbbVie Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.10.5 AbbVie Recent Development
11.11 Eli Lilly and Company
11.11.1 Eli Lilly and Company Company Detail
11.11.2 Eli Lilly and Company Business Overview
11.11.3 Eli Lilly and Company Ulcerative Colitis Treatment Options Introduction
11.11.4 Eli Lilly and Company Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.11.5 Eli Lilly and Company Recent Development
11.12 Amgen
11.12.1 Amgen Company Detail
11.12.2 Amgen Business Overview
11.12.3 Amgen Ulcerative Colitis Treatment Options Introduction
11.12.4 Amgen Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.12.5 Amgen Recent Development
11.13 Takeda Pharmaceuticals Company
11.13.1 Takeda Pharmaceuticals Company Company Detail
11.13.2 Takeda Pharmaceuticals Company Business Overview
11.13.3 Takeda Pharmaceuticals Company Ulcerative Colitis Treatment Options Introduction
11.13.4 Takeda Pharmaceuticals Company Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.13.5 Takeda Pharmaceuticals Company Recent Development
11.14 Ferring Pharmaceuticals
11.14.1 Ferring Pharmaceuticals Company Detail
11.14.2 Ferring Pharmaceuticals Business Overview
11.14.3 Ferring Pharmaceuticals Ulcerative Colitis Treatment Options Introduction
11.14.4 Ferring Pharmaceuticals Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.14.5 Ferring Pharmaceuticals Recent Development
11.15 InDeX Pharmaceuticals
11.15.1 InDeX Pharmaceuticals Company Detail
11.15.2 InDeX Pharmaceuticals Business Overview
11.15.3 InDeX Pharmaceuticals Ulcerative Colitis Treatment Options Introduction
11.15.4 InDeX Pharmaceuticals Revenue in Ulcerative Colitis Treatment Options Business (2018-2023)
11.15.5 InDeX Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 潰瘍性大腸炎治療オプションのグローバル市場2023年：抗炎症薬、免疫抑制剤、その他医薬品(Global Ulcerative Colitis Treatment Options Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

潰瘍性大腸炎治療オプションのグローバル市場2023年：抗炎症薬、免疫抑制剤、その他医薬品

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp